Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859839 | 0.82 | BRD4 (0.47) | BRD4SRD5A1SRD5A2BRD2DDB1 | |
| SCHEMBL26788780 | 0.82 | BRD4 (0.47) | BRD4SRD5A1SRD5A2BRD2DDB1 | |
| SCHEMBL23107033 | 0.82 | BRD4 (0.47) | BRD4SRD5A1SRD5A2BRD2DDB1 | |
| SCHEMBL31027444 | 0.80 | BRD4 (0.66) | BRD4SRD5A1SRD5A2BRD2DDB1 | |
| SCHEMBL15850804 | 0.79 | — | — | |
| SCHEMBL21475939 | 0.78 | BRD4 (0.46) | BRD4SRD5A1SRD5A2BRD2CYP11B2 | |
| SCHEMBL31126751 | 0.78 | BRD4 (0.41) | BRD4SRD5A1SRD5A2BRD2 | |
| SCHEMBL19296766 | 0.77 | BRD4 (0.43) | BRD4SRD5A1SRD5A2BRD2CYP11B2 | |
| SCHEMBL27737854 | 0.77 | BRD4 (0.40) | BRD4SRD5A1SRD5A2BRD2 | |
| SCHEMBL27758738 | 0.77 | BRD4 (0.40) | BRD4SRD5A1SRD5A2BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| WO-2024264072-A2 | PARP INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | BRD4 120/4885SRD5A1 3385/4885NCF1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.